GT Biopharma

GT Biopharma is a clinical-stage biotechnology company developing immunotherapies that activate and direct natural killer (NK) cells against cancer. Its proprietary Tri-specific Killer Engager (TriKE) platform combines tumor-targeting antibodies with an interleukin-15 component designed to stimulate NK cell proliferation and activity. The company's operating model centers on drug discovery, protein engineering, clinical development, and partnerships supporting therapeutic manufacturing. Its pipeline includes GTB-3650, a CD33-targeted TriKE therapy for myeloid malignancies, alongside additional candidates targeting hematologic cancers and solid tumors. Its strategic focus centers on advancing NK cell engager therapies through clinical trials and expanding the TriKE platform across oncology indications.